Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–80
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 18 years
Histological confirmed diagnosis of carcinoma of the prostate
Current or previous evidence of metastatic disease to the bone
Receiving currently or not, hormonal therapy
ECOG performance status of 0, 1, or 2
You may not be if
Patients with abnormal renal function as evidenced by either a serum creatinine determination 1.5 x or greater above the upper limit of normal, or by a calculated creatinine clearance of 60 ml/minute or less.
Corrected serum calcium concentration, adjusted for serum albumin \< 8.0 mg/dl (2.00 mmol/L).
Liver function tests \>2.5 ULN, serum creatinine \>1.5 ULN.
Patients with another non malignant disease, which could confound the evaluation of primary endpoints, or prevent the patient complying with the protocol.
Known hypersensitivity to zoledronic acid or other bisphosphonates or each of the compounds which perform the formula.
Clareo Health | Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
